Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ulcer 1Tomaculous neuropathy 1Thrombocythemia, Essential 1Stomatitis 1Stomach Neoplasms 1Radiation Pneumonitis 1Primary Myelofibrosis 1Polycythemia Vera 1Polycystic Ovary Syndrome 1Neuroma 1Myeloproliferative Disorders 1Median Neuropathy 1Lung Neoplasms 1Lung Diseases, Interstitial 1Hand Injuries 1Disease 1Carpal Tunnel Syndrome 1Breast Neoplasms 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 48Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × Acetylcysteine × Clear all
NCT07117630 2026-05-19

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Fudan University

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡